Physical decline and cognitive impairment in frail hypertensive elders during COVID-19

Mone, Pasquale; Pansini, Antonella; Frullone, Salvatore; Donato, Antonio de; Buonincontri, Veronica; Blasiis, Paolo De; Marro, Anna; Morgante, Maria; Luca, Antonio De; Santulli, Gaetano

doi:10.1016/j.ejim.2022.03.012

Cited by 30 publications

(16 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In a cohort of elderly patients suffering both hypertension and frailty, a correlation between physical decline and cognitive impairment was found. This evidence further stresses the role of comorbidities in the context of sarcopenia [ 39 ]; thus frailty represents an additional problem to be considered along with the control of blood pressure in older adults. More in general, frailty is frequently accompanied by comorbidities such as diabetes, heart failure, and hypertension in older subjects; therefore, a form of prevention of sarcopenia could result from better management of these populations of patients [ 40 ].…”

Section: Discussionmentioning

confidence: 77%

Beneficial Effect of H2S-Releasing Molecules in an In Vitro Model of Sarcopenia: Relevance of Glucoraphanin

Micheli

Mitidieri

Turnaturi

et al. 2022

IJMS

View full text Add to dashboard Cite

Sarcopenia is a gradual and generalized skeletal muscle (SKM) syndrome, characterized by the impairment of muscle components and functionality. Hydrogen sulfide (H2S), endogenously formed within the body from the activity of cystathionine-γ-lyase (CSE), cystathionine- β-synthase (CBS), and mercaptopyruvate sulfurtransferase, is involved in SKM function. Here, in an in vitro model of sarcopenia based on damage induced by dexamethasone (DEX, 1 μM, 48 h treatment) in C2C12-derived myotubes, we investigated the protective potential of exogenous and endogenous sources of H2S, i.e., glucoraphanin (30 μM), L-cysteine (150 μM), and 3-mercaptopyruvate (150 μM). DEX impaired the H2S signalling in terms of a reduction in CBS and CSE expression and H2S biosynthesis. Glucoraphanin and 3-mercaptopyruvate but not L-cysteine prevented the apoptotic process induced by DEX. In parallel, the H2S-releasing molecules reduced the oxidative unbalance evoked by DEX, reducing catalase activity, O2− levels, and protein carbonylation. Glucoraphanin, 3-mercaptopyruvate, and L-cysteine avoided the changes in myotubes morphology and morphometrics after DEX treatment. In conclusion, in an in vitro model of sarcopenia, an impairment in CBS/CSE/H2S signalling occurs, whereas glucoraphanin, a natural H2S-releasing molecule, appears more effective for preventing the SKM damage. Therefore, glucoraphanin supplementation could be an innovative therapeutic approach in the management of sarcopenia.

show abstract

Section: Discussionmentioning

confidence: 77%

Beneficial Effect of H2S-Releasing Molecules in an In Vitro Model of Sarcopenia: Relevance of Glucoraphanin

Micheli

Mitidieri

Turnaturi

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Frailty onset is due to the failure of multiple organs and/or systems and many pathologic conditions have been associated with frailty ( Walston et al, 2008 ; Afilalo et al, 2014 ; Mone and Pansini, 2020 ; Mone et al, 2021a ; Waite et al, 2021 ; Mone et al, 2022e ). In 2001, Fried et al (2001) developed the five criteria now routinely used to diagnose frailty.…”

Section: Introductionmentioning

confidence: 99%

Functional role of miR-34a in diabetes and frailty

et al. 2022

Self Cite

View full text Add to dashboard Cite

Emerging evidence has shown that microRNAs (miRNAs) play critical role in the pathogenesis of several disorders. In the present minireview, we focus our attention on the functional role of a specific miRNA, namely miR-34a, in the pathophysiology of frailty and diabetes mellitus. Based on the current literature, we speculate that this miRNA may serve as a potential biomarker of frailty in diabetic older adults. Additionally, its actions on oxidative stress might represent a druggable target to obtain new potentials treatments.

show abstract

“…Consistently, in a population of community‐dwelling frail older adults with hypertension, it has been observed a consensual impairment of physical and cognitive performances during COVID‐19 pandemic. 41 In a Japanese cohort of older adults assessed during COVID‐19 outbreak, it has been estimated a transition rate from non‐frailty to frailty over 6 months of roughly 10%. 42 Another study showed an increase of prevalence of social frailty with 10.7% of subjects who converted from robust to social frailty during one‐year follow‐up before and after the declaration of the state of emergency.…”

Section: Discussionmentioning

confidence: 99%

Frailty trajectories in community‐dwelling older adults during COVID‐19 pandemic: The PRESTIGE study

Custodero

Zora²,

Poli

et al. 2022

Eur J Clin Investigation

View full text Add to dashboard Cite

Background Frailty has been recognized as potential surrogate of biological age and relevant risk factor for COVID‐19 severity. Thus, it is important to explore the frailty trajectories during COVID‐19 pandemic and understand how COVID‐19 directly and indirectly impacts on frailty condition. Methods We enrolled 217 community‐dwelling older adults with available information on frailty condition as assessed by multidimensional frailty model both at baseline and at one‐year follow‐up using Multidimensional Prognostic Index (MPI) tools. Pre‐frail/frail subjects were identified at baseline as those with MPI score >0.33 (MPI grades 2–3). Frailty worsening was defined by MPI difference between 12 months follow‐up and baseline ≥0.1. Multivariable logistic regression was modelled to identify predictors of worsening of frailty condition. Results Frailer subjects at baseline (MPI grades 2–3 = 48.4%) were older, more frequently female and had higher rates of hospitalization and Sars‐CoV‐2 infection compared to robust ones (MPI grade 1). Having MPI grades 2–3 at baseline was associated with higher risk of further worsening of frailty condition (adjusted odd ratio (aOR): 13.60, 95% confidence interval (CI): 4.01–46.09), independently by age, gender and Sars‐CoV‐2 infection. Specifically, frail subjects without COVID‐19 (aOR: 14.84, 95% CI: 4.26–51.74) as well as those with COVID‐19 (aOR: 12.77, 95% CI: 2.66–61.40, p = 0.001) had significantly higher risk of worsening of frailty condition. Conclusions Effects of COVID‐19 pandemic among community‐dwelling frailer individuals are far beyond the mere infection and disease, determining a significant deterioration of frailty status both in infected and non‐infected subjects.

show abstract

Physical decline and cognitive impairment in frail hypertensive elders during COVID-19

Cited by 30 publications

References 32 publications

Beneficial Effect of H2S-Releasing Molecules in an In Vitro Model of Sarcopenia: Relevance of Glucoraphanin

Beneficial Effect of H2S-Releasing Molecules in an In Vitro Model of Sarcopenia: Relevance of Glucoraphanin

Functional role of miR-34a in diabetes and frailty

Frailty trajectories in community‐dwelling older adults during COVID‐19 pandemic: The PRESTIGE study

Contact Info

Product

Resources

About